

Figure S1. Scatter plot showing the difference and overlaps in gene regulation between different treatments. A. Comparison between beclomethasone and combined beclomethasone and amputation treatment. For all genes showing significant regulation upon beclomethasone (green and grey dots) or the combined beclomethasone and amputation treatment (blue and grey dots), the fold change due to beclomethasone and amputation treatment was plotted as a function of the fold change due to beclomethasone. The plot shows a large group of genes (grey dots) regulated by both treatments. B. Comparison between amputation and beclomethasone treatment. For all genes showing significant regulation upon amputation (red and grey dots) or beclomethasone treatment (green and grey dots), the fold change due to beclomethasone treatment was plotted as a function of the fold change due to amputation. The plot shows a very small group of genes (grey dots) regulated by both treatments. The grey line indicates the point at which the two different treatment have the same effect. Significantly regulated genes were selected by using a $p_{adj} < 0.05$ and $|\text{FoldChange}| > 2$ cutoff.






Figure S2. Gene ontology analysis of RNA sequencing experiment. A. The number of KEGG pathways overrepresented in clusters of genes significantly regulated by amputation, beclomethasone, and amputation+beclomethasone. Amputation regulated pathways involved in the immune system and in metabolism. Amputation+beclomethasone treatment regulated a lower number of regulated pathways involved in both the immune system and metabolism. B. The number of regulated genes involved in the overrepresented pathways. Amputation regulated genes involved in immune- and metabolism-related pathways. Amputation+beclomethasone regulated a lower number of genes involved in these pathways.






Figure S3. Significantly enriched KEGG pathways mapped with gene expression level. In the oxidative phosphorylation (A), Citrate cycle (TCA cycle) (B) and Glycolysis/ Gluconeogenesis (C) pathways, the fold change of the genes is indicated by different colour and the intensity of the colour as shown in the scale. The three colour shown in one gene indicated the logarithm fold change of amputation, beclomethasone and amputation+beclomethasone treatment respectively. The maps show that the vast majority of the amputation-induced changes in gene expression are inhibited by beclomethasone treatment in these pathways.




Figure S4. Expression levels of immune-related genes in FACS-sorted macrophages, determined by qPCR for *arg2*, *cxcr4b*, *tgfb1*, *ccr2* (A) at 24hpa in 3 dpf larvae. The expression level of *cxcr4b* was increased by beclomethasone treatment. Statistical analysis were performed by ANOVA with a Fisher's LSD post hoc. Values shown are the means \pm s.e.m. of three independent experiments. Statistical significance is indicated by: * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.




Figure S5. Effect of beclomethasone on the morphology of macrophages. The percentage of macrophages with different levels of circularity (0.0-0.5 and 0.5-1.0) were determined over time for the control group (A) and beclomethasone-treated group (B). In the control group, an increase in the percentage of macrophages with a circularity level between 0.0 and 0.5 and a decrease in the percentage of macrophages with a level between 0.5 and 1.0 was observed. In the beclomethasone-treated group, these changes were not observed. Values shown are means \pm s.e.m..

Table S1. KEGG-pathways, based on RNA sequencing analysis.**Amputation**

Term	Count	%	P-value	Fold Enrichment
Immune system				
NOD-like receptor signaling pathway	6	1.03	2.89E-02	3.43
Toll-like receptor signaling pathway	8	1.37	6.13E-02	2.26
Cytokine-cytokine receptor interaction	11	1.89	6.58E-02	1.88
Jak-STAT signaling pathway	8	1.37	9.53E-02	2.04
Metabolism				
Oxidative phosphorylation	28	4.81	2.08E-13	5.60
Carbon metabolism	23	3.95	2.72E-10	5.15
Biosynthesis of antibiotics	31	5.33	4.11E-10	3.73
Metabolic pathways	83	14.26	1.20E-09	1.84
Glycolysis / Gluconeogenesis	17	2.92	3.07E-09	6.52
Biosynthesis of amino acids	13	2.23	3.87E-05	4.28
Arginine and proline metabolism	10	1.72	1.33E-04	5.00
Pentose phosphate pathway	7	1.20	6.51E-04	6.32
Citrate cycle (TCA cycle)	6	1.03	5.67E-03	5.09
Fructose and mannose metabolism	6	1.03	1.42E-02	4.10
Pyruvate metabolism	6	1.03	1.73E-02	3.91
Galactose metabolism	5	0.86	2.82E-02	4.24
Insulin resistance	10	1.72	4.62E-02	2.11
Glycine, serine and threonine metabolism	5	0.86	7.43E-02	3.11
Propanoate metabolism	4	0.69	7.54E-02	4.00
RNA degradation	7	1.20	8.06E-02	2.31
Others				
Cardiac muscle contraction	13	2.23	1.30E-04	3.79

Amputation & Beclomethasone


Term	Count	%	P-value	Fold Enrichment
Immune system				
Toll-like receptor signaling pathway	6	1.97	8.62E-03	4.64
Metabolism				
Insulin signaling pathway	10	3.28	3.19E-04	4.45
Starch and sucrose metabolism	5	1.64	6.92E-04	11.96
Insulin resistance	8	2.62	1.49E-03	4.60
Steroid hormone biosynthesis	4	1.31	1.16E-02	8.27
FoxO signaling pathway	7	2.30	2.16E-02	3.15
Biosynthesis of antibiotics	8	2.62	2.94E-02	2.63
Arginine biosynthesis	3	0.98	3.76E-02	9.57
Glyoxylate and dicarboxylate metabolism	3	0.98	6.69E-02	6.96
Galactose metabolism	3	0.98	6.69E-02	6.96
Glycolysis / Gluconeogenesis	4	1.31	6.72E-02	4.19
Retinol metabolism	3	0.98	8.94E-02	5.89
Alanine, aspartate and glutamate metabolism	3	0.98	9.33E-02	5.74
Others				
Adipocytokine signaling pathway	5	1.64	2.43E-02	4.45

Beclomethasone

Term	Count	%	P-value	Fold Enrichment
Metabolism				
FoxO signaling pathway	8	4.08	1.48E-03	4.57
Insulin signaling pathway	8	4.08	1.59E-03	4.51
Insulin resistance	6	3.06	1.06E-02	4.38
Glyoxylate and dicarboxylate metabolism	3	1.53	4.35E-02	8.82
Steroid hormone biosynthesis	3	1.53	5.35E-02	7.87
Others				
Focal adhesion	7	3.57	3.80E-02	2.74
Adipocytokine signaling pathway	4	2.04	5.57E-02	4.51

Table S2. Sequences of Primers used in qPCR reactions.

Gene name	Gene accession	Sequence (5'-3')
<i>ppail</i>	ENSDARG00000103994	Fw: CATCCACAACCTTCCCGAACAC Rv: AACTGAAACACGGAGGCAAAG
<i>ccl2</i>	ENSDARG00000041835	Fw: GTCTGGTGCTCTTCGCTTTC Rv: TGCAGAGAAGATGCGTCGTA
<i>cxcl11aa</i>	ENSDARG00000100662	Fw: ACTCAACATGGTGAAGCCAGTGCT Rv: CTTCAGCGTGGCTATGACTTCCAT
<i>il8</i>	ENSDARG00000104795	Fw: TGTGTTATTGTTTTCTGGCATTTC Rv: GCGACAGCGTGGATCTACAG
<i>cxcl18b</i>	ENSDARG00000075045	Fw: TCTTCTGCTGCTGCTTGCGGT Rv: GGTGTCCCTGCGAGCACGAT
<i>il6</i>	ENSDARG00000102318	Fw: CGCTAAGGCAACTGGAAGAC Rv: CCAGACCACTGGGAAACT
<i>il1b</i>	ENSDARG00000098700	Fw: TGTGTGTTTGGGAATCTCCA Rv: CTGATAAACCAACCGGGACA
<i>tnfa</i>	ENSDARG00000009511	Fw: ACCAGGCCTTTTCTTCAGGT Rv: TTTGCCTCCGTAGGATTCAG
<i>mmp9</i>	ENSDARG00000042816	Fw: CATTAAAGATGCCCTGATGTATCCC Rv: AGTGGTGGTCCGTGGTTGAG
<i>arg2</i>	ENSDARG00000039269	Fw: AAGGCCATTCTCAGCAGTGT Rv: AGGTTTCCCGAAGGTGAAGT
<i>cxcr4b</i>	ENSDART00000061499	Fw: GCGACCTCTCAGTCAGCAAT Rv: TCACAAGCACCAAGTCCA
<i>tgfb1</i>	ENSDARG00000041502	Fw: CAACCGCTGGCTCTCATTTGA Rv: ACAGTCGCAGTATAACCTCAGCT
<i>ccr2</i>	ENSDARG00000079829	Fw: TGGCAACGCAAAGGCTTTCAGTGA Rv: AGGTTTCCCGAAGGTGAAGT



Movie 1. Macrophage migration upon tail amputation. Tracks of macrophages migrating between 1.5 and 5.5 hpa in 3 dpf larvae in the vehicle-treated group. Confocal microscopy images were analyzed using ImageJ with custom-made plugins, developed by Dr. Joost Willemse (Leiden University), for localization and tracking of cells.



Movie 2. Neutrophil migration upon tail amputation. Tracks of neutrophils migrating between 1.5 and 5.5 hpa in 3 dpf larvae in the vehicle-treated group. Confocal microscopy images were analyzed using ImageJ with custom-made plugins, developed by Dr. Joost Willemsse (Leiden University), for localization and tracking of cells.